Literature DB >> 17339753

Expression of the MDR1 gene and P-glycoprotein in canine mast cell tumor cell lines.

Munekazu Nakaichi1, Yoko Takeshita, Masaru Okuda, Yuya Nakamoto, Kazuhito Itamoto, Satoshi Une, Nobuo Sasaki, Tsuyoshi Kadosawa, Tomoko Takahashi, Yasuho Taura.   

Abstract

Cellular drug resistance to antineoplastic drugs is often due to the presence of a drug efflux pump that reduces intracellular drug accumulation and chemosensitivity. P-glycoprotein (P-gp), which is encoded by the MDR1 gene, is considered to function as an ATP-driven membrane drug efflux pump and appears to play an important role in tumor cell resistance. In the present report, we assessed the expression of MDR1 by RT-PCR in three canine mast cell tumor cell lines, TiMC, CoMS and LuMC, originating from a cutaneous tumor, an oral-mucosal tumor and a gastrointestinal tumor, respectively. P-gp expression was also examined by Western blot analysis, while the functional activity of P-gp was assessed by flowcytometric analysis of intracellular rhodamine-123 (Rhd-123) uptake. The results revealed that MDR1 gene and P-gp were both expressed in CoMS and LuMC cells, whereas neither was present in TiMC cells. In CoMS and LuMC cells, intracellular uptake of Rhd-123 increased in the presence of verapamil, a functional modulator of P-gp. In contrast, TiMC cells did not show any changes in the intracellular accumulation of Rhd-123 after the verapamil addition. These findings suggest that the expressions of MDR1 gene and P-gp probably contribute to cellular drug resistance in canine mast cell tumors.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17339753     DOI: 10.1292/jvms.69.111

Source DB:  PubMed          Journal:  J Vet Med Sci        ISSN: 0916-7250            Impact factor:   1.267


  4 in total

Review 1.  Mechanisms of Drug Resistance in Veterinary Oncology- A Review with an Emphasis on Canine Lymphoma.

Authors:  Maurice Zandvliet; Erik Teske
Journal:  Vet Sci       Date:  2015-08-12

2.  High-throughput screening system for dynamic monitoring of exocytotic vesicle trafficking in mast cells.

Authors:  Takeshi Kiyoi; Shuang Liu; Muhammad Novrizal Abdi Sahid; Masachika Shudou; Kazutaka Maeyama; Masaki Mogi
Journal:  PLoS One       Date:  2018-06-08       Impact factor: 3.240

Review 3.  Diagnosis, Prognosis and Treatment of Canine Cutaneous and Subcutaneous Mast Cell Tumors.

Authors:  Andrigo Barboza de Nardi; Rodrigo Dos Santos Horta; Carlos Eduardo Fonseca-Alves; Felipe Noleto de Paiva; Laís Calazans Menescal Linhares; Bruna Fernanda Firmo; Felipe Augusto Ruiz Sueiro; Krishna Duro de Oliveira; Silvia Vanessa Lourenço; Ricardo De Francisco Strefezzi; Carlos Henrique Maciel Brunner; Marcelo Monte Mor Rangel; Paulo Cesar Jark; Jorge Luiz Costa Castro; Rodrigo Ubukata; Karen Batschinski; Renata Afonso Sobral; Natália Oyafuso da Cruz; Adriana Tomoko Nishiya; Simone Crestoni Fernandes; Simone Carvalho Dos Santos Cunha; Daniel Guimarães Gerardi; Guilherme Sellera Godoy Challoub; Luiz Roberto Biondi; Renee Laufer-Amorim; Paulo Ricardo de Oliveira Paes; Gleidice Eunice Lavalle; Rafael Ricardo Huppes; Fabrizio Grandi; Carmen Helena de Carvalho Vasconcellos; Denner Santos Dos Anjos; Ângela Cristina Malheiros Luzo; Julia Maria Matera; Miluse Vozdova; Maria Lucia Zaidan Dagli
Journal:  Cells       Date:  2022-02-10       Impact factor: 6.600

4.  Development of an in vitro model of acquired resistance to toceranib phosphate (Palladia®) in canine mast cell tumor.

Authors:  Charles H C Halsey; Daniel L Gustafson; Barbara J Rose; Amber Wolf-Ringwall; Robert C Burnett; Dawn L Duval; Anne C Avery; Douglas H Thamm
Journal:  BMC Vet Res       Date:  2014-05-06       Impact factor: 2.741

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.